Is Exelixis, Inc. (EXEL) One of the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies?
From Yahoo Finance: 2025-05-11 16:52:00
Jim Simons’ Renaissance Technologies, a quantitative trading firm, continues to shine even after his passing. The Medallion Fund boasts impressive returns, with an annual average of 31.5%. Simons’ net worth at the time of his death was $31.4 billion, thanks to the strong market performance of the fund and Renaissance.
Renaissance Technologies’ Institutional Diversified Alpha Fund gained 9.05% in February, building on its 2024 return of 15.6%. The Institutional Equities Fund rose 11.85%, its best start in over a decade. Both funds use stock index futures and options to manage risk, but unwinding sizable holdings may impact market prices.
Exelixis, Inc. (EXEL) is a top stock pick by Jim Simons’ Renaissance Technologies, focusing on developing targeted cancer treatments. The FDA approved its drug Cabometyx for certain neuroendocrine tumors, marking the company’s sixth approval in the US. Analysts predict strong performance for Exelixis due to its prescription model.
Exelixis, Inc. (EXEL) ranks 9th on the list of best stocks to buy according to Jim Simons’ Renaissance Technologies. While the potential for EXEL is acknowledged, some AI stocks may offer greater returns in a shorter timeframe. Investors seeking promising AI stocks can explore opportunities beyond EXEL for potential gains.